V116
Phase 3Biologic
Merck & Co.V116 is one of 67 biologic programs targeting Immunodeficiency. It is currently in Phase 3.
2
Indications
11
Total Trials
0
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
V116
Merck & Co.Phase 3
Fluzone
GSKPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunogenicity6 trials
Show 3 more trials
Influenza1 trial
Immunodeficiency1 trial
Pneumococcal Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for V116. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company